The January 2024 issue of the CytexOrtho newsletter covers our 2023 accomplishments, including receiving Breakthrough Device Designation from the FDA, and highlights what is on the horizon in 2024: the plan for hosting our first clinical trial and the launch of our Series A campaign! If you would like to receive a copy of our future newsletters, be sure to sign up for our mailing lists on the Contact Us page.
![](https://cytexortho.com/wp-content/uploads/2024/01/1-2-791x1024.png)
![](https://cytexortho.com/wp-content/uploads/2024/01/2-2-791x1024.png)
![](https://cytexortho.com/wp-content/uploads/2024/01/3-2-791x1024.png)
![](https://cytexortho.com/wp-content/uploads/2024/02/Untitled-design-959x1024.png)
![](https://cytexortho.com/wp-content/uploads/2024/01/5-1-791x1024.png)